TAMOXIFEN IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER

Tamoxifen was administered to 30 patients with persistent or recurrent epithelial ovarian cancer following initial plantinum-based chemother apy. Two complete remissions (lasting 41 months and 12 months, respect ively) were documented (6.6%), while 10 patients (33.3%) had stabiliza tion of disease for a mean duration of 11.5 months. Tamoxifen was not associated with any significant toxicity and is a reasonable therapeut ic option for patients with persistent or recurrent. ovarian cancer, a lthough it is only associated with modest activity. This paper reviews our experience with tamoxifen and summarizes the world literature.